Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | DCK | P27707 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.40 |
| ▸ | VCP | P55072 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31494442 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2RAB9ANPC1DCKLMNA | |
| SCHEMBL27218667 | 0.80 | SMN1; SMN2 (0.49) | SMN1; SMN2RAB9ANPC1DCKLMNA | |
| SCHEMBL27218703 | 0.78 | MAPT (0.50) | LOXL2SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL1520825 | 0.76 | RAB9A (0.78) | SMN1; SMN2RAB9ANPC1HTTVCP | |
| SCHEMBL27218700 | 0.75 | SMN1; SMN2 (0.62) | SMN1; SMN2RAB9ANPC1LMNAMAPT | |
| SCHEMBL31494316 | 0.75 | SMN1; SMN2 (0.62) | SMN1; SMN2RAB9ANPC1LMNAMAPT | |
| SCHEMBL27218767 | 0.74 | SMN1; SMN2 (0.55) | SMN1; SMN2RAB9ANPC1DCKLMNA | |
| SCHEMBL27218883 | 0.73 | MPO (0.55) | SMN1; SMN2RAB9ANPC1DCKLMNA | |
| SCHEMBL31494430 | 0.71 | SMN1; SMN2 (0.72) | SMN1; SMN2RAB9ANPC1LMNAMAPT | |
| SCHEMBL31494436 | 0.71 | RAB9A (0.46) | SMN1; SMN2RAB9ANPC1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4232448-B1 | AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR | Halo Therapeutics Ltd (GB) | 2025-05-07 | — | — | EP | disclosed |
| US-20240158382-A1 | Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor | Halo Therapeutics Ltd (GB) | 2024-05-16 | — | — | US | disclosed |
| US-20220274968-A1 | Oxazole And Oxadiazole Derivatives Useful As Agonists Of Free Fatty Acid Receptor 1 | GBIOTECH S.À.R.L. (CH) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158382-A1 | Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor | FFAR1, FFAR2, FFAR3 | LOXL2 569/4885SMN1; SMN2 1802/4885RAB9A 2474/4885 |
| US-20220274968-A1 | Oxazole And Oxadiazole Derivatives Useful As Agonists Of Free Fatty Acid Receptor 1 | FFAR2, FFAR1, FFAR3 | LOXL2 846/4885SMN1; SMN2 3576/4885RAB9A 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.